Skip to content
Telehealth Graded
Peptide evidence

Sermorelin: the peptide that used to be an approved drug

Sermorelin is the unusual peptide on a telehealth menu: it was once an approved American drug, sold as Geref, and the FDA's own record says it wasn't pulled for safety or effectiveness reasons. What it doesn't have is modern evidence. Nineteen randomized trials exist and the newest is from 2005 — zero have been published since 2010, against 313 for semaglutide over the same window.

Evidence read September 2026. Nobody here holds a medical license and none of this is medical advice. Every source below is listed so you can check it yourself.

What this comes down to

  • Sermorelin acetate was approved twice — 1990 and 1997, both as Geref — and both products are discontinued. Drugs@FDA flags a Federal Register determination that neither was withdrawn for safety or effectiveness reasons.
  • Nineteen randomized trials exist. None published since 2010, and most of the older ones test how the pituitary responds rather than whether anyone got better.
  • Sermorelin does not appear on the FDA's list of compounding substances with identified safety risks, which is unusual for a peptide sold this way.
  • The best adult data is a 16-week trial in 19 people aged 55 to 71, and it found benefits in men that it did not find in women.
Randomized trials
19
None since 2010
FDA approvals
2, both discontinued
On the FDA safety-risk list
No
Largest adult trial
19 participants

It was a real drug, and then it wasn't

Geref, the brand name for sermorelin acetate, was approved in December 1990 and again in a second formulation in September 1997, both to EMD Serono. Both are listed as discontinued in Drugs@FDA, and both carry the same annotation: a Federal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons[1]. Companies retire drugs for commercial reasons all the time — recombinant growth hormone was cheaper and simpler than a peptide that asks the pituitary to make its own.

That history is doing real work in how sermorelin gets sold. A peptide with a lapsed approval reads very differently from one that never had one, and it explains why sermorelin isn't on the FDA's list of nominated compounding substances with identified safety risks[3]. Plenty of the peptides these same menus sell are on it.

The absence, with its census

The FDA's published table of compounding substances that may present significant safety risks

Full-text read of the FDA page, searching for “sermorelin” across both the category 2 table and the withdrawn-nominations table

Returned 0. Positive control — “ipamorelin” on the same page, same read — returned 6 through the identical filter in the same session. Read September 2026.

The page's own face date is April 22, 2026. The control matters because a zero from a search of a page proves nothing unless something else on that page matches.

Nineteen trials, and what they were actually testing

Most of the sermorelin literature is diagnostic. Growth hormone releasing hormone was used to find out whether a child's pituitary could respond, and a lot of the trials are dose-response studies in that setting rather than tests of whether sermorelin changes anything a patient would notice. The newest randomized trial indexed is from 2005.

The search behind that claim

PubMed, via the E-utilities API

sermorelin AND "randomized controlled trial"[pt] AND 2010:2026[dp]

Returned 0. Positive control — semaglutide, identical filter and date range — returned 313 through the identical filter in the same session. Read September 2026.

Tesamorelin, a closely related and much smaller peptide drug, returned 22 through the same filter and date range. Dropping the date range, sermorelin returns 19 randomized trials in total.

The trial closest to what a telehealth buyer is actually being sold ran for 16 weeks in ten women and nine men aged 55 to 71, published in the Journal of Clinical Endocrinology and Metabolism in 1997[2]. Nightly injection raised nocturnal growth hormone and IGF-I, and increased skin thickness in both sexes. Lean body mass, insulin sensitivity, general well-being and libido improved in men and not in women. Body weight and bone mineral density didn't move in either group. The only adverse effect reported was transient high blood lipids, which resolved.

Two caveats that change how you read it

It was single-blind, not double-blind, and it used a modified form of the peptide rather than sermorelin itself — the paper describes [Nle27]GHRH-(1-29)-NH2. Nineteen people for sixteen weeks is also a pilot, not a verdict. It is nonetheless the most relevant human data that exists, which tells you how thin the field is.

What to ask a company selling it

Sermorelin is dispensed as a compounded preparation, so the questions are the compounding questions: which pharmacy made it, whether that pharmacy is a state-licensed 503A or an FDA-registered outsourcing facility, and what the vial's beyond-use date is. Those two categories are held to different quality standards — outsourcing facilities are subject to current good manufacturing practice requirements and 503A pharmacies are not[4].

Then the price question, which is the one this site exists for. Peptide programs are priced the same way GLP-1 programs are: a low headline that turns out to be a prepaid annual rate divided by twelve. We publish the month-to-month figure and show the gap — how we verify prices covers what sits behind each number, and what “starting at” actually costs you covers how the headline gets built.

Questions people actually ask

Is sermorelin FDA-approved?

Not currently. It was approved as Geref in 1990 and again in 1997, and both products are discontinued. Drugs@FDA notes a Federal Register determination that neither was pulled for safety or effectiveness reasons, which is a meaningful distinction — but a discontinued approval is not an active one.

Does sermorelin work for weight loss?

The trial record doesn't support that claim. The 16-week study in older adults found no change in body weight in either sex, and increases in lean mass only in men. Nothing in the randomized literature tests sermorelin as a weight-loss treatment.

How is sermorelin different from tesamorelin?

Both are growth-hormone-releasing peptides, but tesamorelin has an active approval, a specific indication, and 26 randomized trials behind it. Sermorelin has a lapsed approval and 19 trials, none since 2010.

Why isn't sermorelin on the FDA's peptide safety list?

The list covers substances nominated for the compounding bulks list, and the agency's concerns there are largely about peptides it has little or no human safety information for. Sermorelin has a prior approval and a decade of trial data, thin as that data is, so it isn't in the same position as a peptide that has never been through a review.

Sources

Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it.

  1. Drugs@FDA: FDA-Approved Drugs, queried through the openFDA API. U.S. Food and Drug Administration, 2026. Source · Read September 2026
    Sermorelin acetate was approved as Geref under NDA 019863 (December 28, 1990) and NDA 020443 (September 26, 1997), both to EMD Serono, and both are listed as discontinued with a Federal Register determination that they were not withdrawn for safety or effectiveness reasons.
  2. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of Clinical Endocrinology and Metabolism, 1997. PMID 9141536 · doi:10.1210/jcem.82.5.3943 · Read September 2026
    A 16-week single-blind randomized trial in ten women and nine men aged 55 to 71 found increased nocturnal growth hormone, IGF-I and skin thickness in both sexes; increased lean body mass, insulin sensitivity, well-being and libido in men only; no change in body weight or bone mineral density; and transient hyperlipidemia as the only adverse effect.
  3. Substances in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, 2026. Source · Document dated April 2026; read September 2026
    Sermorelin does not appear anywhere on the FDA's published table of compounding substances that may present significant safety risks, read in full on the same day the term “ipamorelin” matched six times on the same page.
  4. Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025; read September 2026
    Drugs compounded in outsourcing facilities are subject to current good manufacturing practice requirements; drugs compounded by a licensed pharmacist in a state-licensed pharmacy under section 503A are not.